

PRO PHARMACEUTICALS INC  
Form 8-K  
July 17, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**July 14, 2009**

**Date of Report**

**(Date of earliest event reported)**

# PRO-PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction of  
incorporation or organization)

**000-32877**  
(Commission File Number)

**04-3562325**  
(I.R.S. Employer

Identification No.)

**7 Wells Avenue**

**Newton, Massachusetts 02459**

(Address of principal executive offices) (Zip code)

**(617) 559-0033**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01 Other Events.**

On July 17, 2009, Pro-Pharmaceuticals, Inc. issued a news release that the Suffolk County Superior Court allowed Pro-Pharmaceuticals ( the Company ) motion to dismiss the trade secret lawsuit prosecuted by Prospect Therapeutics, Inc. ( Prospect ) against the Company and its former Chief Executive Officer, David Platt.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

99.1 News release of Pro-Pharmaceuticals, Inc. entitled Pro-Pharmaceuticals Prevails in Trade Secret Lawsuit , dated July 17, 2009.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ Anthony D. Squeglia  
Anthony D. Squeglia  
Chief Financial Officer

Date: July 17, 2009